An observational study in Celiac Disease, Small Bowel Mucosal Atrophy or Lesions and Non-celiac Enteropathies, sponsored by Istituti Clinici Scientifici Maugeri SpA. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-04.
Sponsored by Istituti Clinici Scientifici Maugeri SpA · Observational
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Celiac Disease with a site in Italy — 14 open to participants now, 16 under way, none of them phase 3. Celiac Disease · Italy.
Among the 61 studies in Celiac Disease with a site in Italy, this one is the 7th largest by planned enrollment of the 26 observational ones that give a count, is one of 4 that started in 2025, is one of 26 observational ones, reaches primary completion later than 14 of the 15 other live ones, and was the 57th registered.
353 studies on the registry are indexed under Celiac Disease; 78 are open to participants now.
Browse Celiac Disease studies →14 of the 61 studies in Celiac Disease with a site in Italy are open now. Recruiting first, the newest first:
University of Palermo · Sites in Italy
Ages 1–14
University of Palermo · Sites in Italy
Ages 18+
University of Bari · Sites in Italy
Ages 1–18
University of Pavia · Sites in Italy
Ages 18+
Istituti Clinici Scientifici Maugeri SpA · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 4 started in 2025.
This study's planned enrollment of 380 is above the median of 185 across 134 observational studies indexed under Celiac Disease.
Median enrollment 50 across the 35 interventional studies, 207 across the 26 observational. Of the 30 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 61 have an industry lead sponsor. The 10 most frequent:
Istituti Clinici Scientifici Maugeri SpA is the lead sponsor of 128 studies on the registry; 52 are open to participants now.
Istituti Clinici Scientifici Maugeri SpA has 2 studies filed under Celiac Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Celiac Disease with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07862101University of BariStrategy For Assessing The Risk Of Type 1 Diabetes In Pediatric Celiac Patients | 2026-12-30 |
| NCT07915063Istituti Clinici Scientifici Maugeri SpAImpact of Mediterranean Diet and Processed Food Consumption on Gastrointestinal Symptoms in Coeliac Patients on a Gluten-Free Diet | 2026-12-31 |
| NCT03017716University of PalermoInflammatory Back Pain and Gluten Free Diet | 2027-01-01 |
| NCT07584473University of PalermoNCWS or IBS/FD in Relatives of CD Patients | 2027-04-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 61 studies in Celiac Disease with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Coeliac disease (CD) is an immune-mediated enteropathy leading to small intestinal mucosal atrophy. Diagnosis relies on serology and duodenal biopsies, but it can be complicated by patchy lesions and differential diagnosis with Non-Celiac Enteropathies (NCEs). This multicenter observational study aims to develop and validate an Artificial Intelligence (AI) system to detect and characterize small bowel mucosal atrophy and other pathological findings using endoscopic imaging. The study involves a retrospective phase for training the AI model and a prospective phase to validate its diagnostic accuracy compared to standard human assessment.
The study is a multicenter observational non-profit study with a total expected duration of 36 months. It aims to address the challenges in diagnosing CD and NCEs, specifically the subjective nature of endoscopic evaluation and inter-observer variability.
The study proceeds in two phases:
The system aims to provide analysis to assist endoscopists, reducing missed lesions and improving diagnostic accuracy.
Validation of the AI system will be performed offline on recorded anonymized endoscopy videos collected prospectively during the validation phase.
Patients undergoing endoscopic investigation of the small bowel (endoscopy or capsule endoscopy) for suspected or known celiac disease, non-celiac enteropathies or other small bowel conditions
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients (\>=18 years) with suspected or confirmed Celiac Disease or Non-Celiac Enteropathies undergoing small bowel endoscopy.
Adult patients (\>=18 years) undergoing small bowel endoscopy who do not have enteropathy or other small bowel pathological lesions (negative controls).
Adult patients (\>=18 years) undergoing small bowel endoscopy who who do not have Celiac Disease or Non-Celiac Enteropathies but have other small bowel pathological lesions.
Diagnostic Performance of the AI System
Evaluation of Accuracy, Sensitivity, and Specificity of the AI system in detecting intestinal mucosal atrophy and other major pathological findings compared to the gold standard (histology/expert consensus).
Time frame: Through study completion (36 months)
Comparison of Diagnostic Performance (No AI-assistance vs AI-assisted)
Comparison of accuracy, sensitivity, and specificity of gastroenterologists performing assessment with and without the assistance of the AI system.
Time frame: Through study completion (36 months)
Inter-observer Agreement
Measurement of agreement between the AI system and expert gastroenterologists in evaluating the extent of mucosal atrophy.
Time frame: Through study completion (36 months)
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Mar 2028, 36 months after the start.
Of 48 observational studies under Celiac Disease, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 83. This study's planned 36 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istituti Clinici Scientifici Maugeri SpA →